A coronavirus vaccine developed by China's Sinovac Biotech was just 50.4% effective at preventing symptomatic infections in a Brazilian trial, researchers said on Tuesday, barely enough for regulatory approval and well below the rate announced last week.
The latest results are a major disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunisation during the second wave of the world's second-deadliest Covid-19 outbreak.
All Access Plan
starting from
~RM12
per month
You can cancel anytime.
Get unlimited access to our articles on web and apps
Add comments to our articles
Bookmark articles to read later
We accept
Already Subscribed?